This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (10)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Jerome B. Simon, MD

JAMA. 1990;264(1):84-85.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Fecal occult blood testing (FOBT) is the simplest and cheapest way to screen the populace for colorectal tumors. Though primarily intended to uncover early malignant neoplasms, it also reveals benign neoplastic polyps.¹ This is a potentially important benefit of FOBT, because most colorectal cancers arise from malignant transformation of benign polyps—the so-called adenoma-carcinoma sequence.² Hence, widespread detection and removal of asymptomatic polyps could dramatically decrease the incidence of bowel cancer, at least in theory. The best studies of FOBT indicate a substantial yield of adenomas—about 20% of individuals with positive test results aged 50 through 59 years, rising to about one third of those over 70 years.³ These are impressive numbers and, on the surface, lend support to those who advocate general FOBT surveillance of middle-aged and elderly people.

In this issue of THE JOURNAL, however, Ransohoff and Lang⁴ argue that a major proportion of small (<1 . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Medicine, Queen's University, Kingston, Ontario.

Footnotes
Reprint requests to Division of Gastroenterology, Queen's University, 78 Barrie St, Kingston, Ontario, Canada, K7L 3J7 (Dr Simon).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?